In patients with endothelial dysfunction, plasma ghrelin level decreases [55]; conversely, the application of exogenous ghrelin can improve endothelial dysfunction in MS patients by increasing nitric oxide bioactivity [34]. This evidence concerns the gene GHRL and myeloid sarcoma.